Elsevier

Annals of Oncology

Volume 20, Issue 7, July 2009, Pages 1163-1169
Annals of Oncology

original articles
quality of life/supportive care/palliative care
Palliative sedation therapy does not hasten death: results from a prospective multicenter study

https://doi.org/10.1093/annonc/mdp048Get rights and content
Under an Elsevier user license
open archive

Abstract

Background: Palliative sedation therapy (PST) is indicated for and used to control refractory symptoms in cancer patients undergoing palliative care. We aimed to evaluate whether PST has a detrimental effect on survival in terminally ill patients.

Methods: This multicenter, observational, prospective, nonrandomized population-based study evaluated overall survival in two cohorts of hospice patients, one submitted to palliative sedation (A) and the other managed as per routine hospice practice (B). Cohorts were matched for age class, gender, reason for hospice admission, and Karnofsky performance status.

Results: Of the 518 patients enrolled, 267 formed cohort A and 251 cohort B. In total, 25.1% of patients admitted to the participating hospices received PST. Mean and median duration of sedation was 4 (standard deviation 6.0) and 2 days (range 0–43), respectively. Median survival of arm A was 12 days [90% confidence interval (CI) 10–14], while that of arm B was 9 days (90% CI 8–10) (log rank = 0.95, P = 0.330) (unadjusted hazard ratio = 0.92, 90% CI 0.80–1.06).

Conclusion: PST does not shorten life when used to relieve refractory symptoms and does not need the doctrine of double effect to justify its use from an ethical point of view.

Key words

end-of-life care
hospice
palliative sedation
refractory symptom
survival

Cited by (0)